Insulin-like growth factor I (IGF-I) and liver cirrhosis;Factor de crecimiento semejante a la insulina tipo I (IGF-I) y cirrosis hepática

Revista Espanola de Enfermedades Digestivas

Volumn 99, Issue 3, 2007, Pages 156-164

  Conchillo, M ^a   Prieto, J ^a   Quiroga, Jorge ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Cirrhosis; IGF I

Indexed keywords

GROWTH HORMONE; PLACEBO; RECOMBINANT SOMATOMEDIN C; SERUM ALBUMIN; SOMATOMEDIN C; RECOMBINANT PROTEIN;

AMINO ACID MALABSORPTION; AUTOCRINE EFFECT; BONE MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; ENDOTOXEMIA; ENERGY METABOLISM; ENTEROPATHY; GONAD FUNCTION; HORMONE ACTION; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HORMONE SYNTHESIS; HUMAN; HYPOGONADISM; INSULIN LIKE GROWTH FACTOR 1 DEFICIENCY; INSULIN RESISTANCE; INTESTINE FUNCTION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION; LOW DRUG DOSE; MALABSORPTION; MALNUTRITION; MUSCLE MASS; NEOPLASM; NONHUMAN; OSTEOPENIA; PARACRINE SIGNALING; PATHOGENESIS; PORTAL HYPERTENSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUGAR MALABSORPTION; TREATMENT OUTCOME; ANIMAL; LIVER; LIVER TUMOR; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; RECOMBINANT PROTEINS;

EID: 34547563874     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Quiroga J, Beloqui O, Castilla A. Cirrhosis. En: Prieto J, Rodés J, Shafritz DA, editors. Hepatobiliary diseases. Berlin: Springer-Verlag; 1992. p. 323-415.
2. Sarin SK, Dhingra N, Bansal A, Malhotra S, Guptan RC. Dietary and nutritional abnormalities in alcoholic liver disease: A comparison with chronic alcoholics without liver disease. Am J Gastroenterol 1997; 92: 777-83.
3. Bruguera Cortada M, Rodés Teixidor J. Cirrosis hepática compensada. En: Bruguera Cortada M, Miño Fugarolas G, Pons Romero F, Moreno Otero R, editores. Tratamiento de las enfermedades hepáticas. Asociación Española para el Estudio del Hígado; 1997. p. 45-50.
4. Ginés P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122-8.
5. Le Roith D. Insulin-like growth factors. N Engl J Med 1997; 336: 633-40.
6. Daughaday WH, Rotwein P. Insulin-like growth factors I and II: Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989; 10: 68-91.
7. Baxter RC. The somatomedins: insulin-like growth factors. Adv Clin Biochem 1986; 25: 49-115.
8. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995; 16: 3-34.
9. Blomsma MC, de Knegt RJ, Dullaart RPF, Jansen PLM. Insulin-like growth factor-1 in liver cirrhosis. J Hepatol 1997; 27: 1133-8.
10. Zapf J, Waldvogel M, Froesch ER. Binding of non-suppressible insulin-like activity to human serum: Evidence for a carrier protein. Arch Biochem Biophys 1975; 168: 638-45.
11. Schmid C. Insulin-like growth factors. Cell Biol Inter 1995; 19: 445-57.
12. Rosenzweig SA. What's new in the IGF-binding proteins? Growth Horm IGF Res 2004; 14: 329-36.
13. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824-54.
14. Scharf JG, Ramadori G, Braulke T, Hartmann H. Synthesis of insulin-like growth factor binding proteins and of the acid-labile subunit in primary cultures of rat hepatocytes, of Kupffer cells, and in cocultures: regulation by insulin, insulin-like growth factor and growth hormone. Hepatology 1996; 23: 818-27.
15. Bale LK, Conover CA. Regulation of insulin-like growth factor binding protein-3 messenger ribonucleic acid expression by insulinlike growht factor I. Endocrinology 1992; 131: 608-14.
16. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997; 18 (6): 801-31.
17. Werner H, Woloschak M, Stannard B, Shen-Orr Z, Roberts Jr CT, Le Roith D. The insulin-like growth factor I receptor: molecular biology, heterogeneity and regulation. In: LeRoith D, editor. Insulinlike growth factors: Molecular and cellular aspects. CRC Press, Boca Raton; 1991. p. 17-47.
18. Yu H, Mistry J, Nicar MJ, Khosravi MJ, Diamandis A, Van Doorn J, et al. Insulin-like growth factors ( IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2,IGFBP-3, IGFBP-6, and ALS) in blood circulation. J Clin Lab Anal 1999; 13: 166-72.
19. Hall K, Hilding A, Thoren M. Determinants of circulating insulin-like growth factor-I. J Endocrinol Invest 1999; 22: 48-57.
20. Rasmussen MH, Frystyk J, Andersen T, Breum L, Christiansen JS, Hilsted J. The impact of obesity, fat distribution, and energy restriction on insulin-like growth factor-1 (IGF-1), IGF-binding protein-3, insulin, and growth hormone. Metabolism 1994; 43: 315-9.
21. Laron Z, Klinger B. Comparison of the growth promoting effects of the insulin-like growth factor I and growth hormone in the early years of life. Acta Paediatr 2000; 889: 38-41.
22. Laron Z, Anin S, Klipper-Aurbach Y, Klinger B. Effects of insulinlike growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet 1992; 339: 1258-61.
23. Russell-Jones DL, Umpleby AM, Hennessy TR, Bowes SB, Shojaee-Moradie F. Use of leucine clamp to demostrate that IGF-I actively stimulates protein synthesis in normal humans (editorial). Am J Physiol 1994; 267: 591-8.
24. Thoren M, Wivall-Helleryd I, Blum W, Hall K. Effects of repeated subcutaneous administration of recombinant human insulin-like growth factor I in adults with growth hormone deficiency. Eur J Endocrinol 1994; 131: 33-40.
25. Welle S, Thronton C, Statt M, McHenry B. Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab 1996; 81: 3239-43.
26. Boulware SD, Tamborlane WV, Matthews LS, Sherwin RS. Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism. Am J Physiol 1992; 262: E130-3.
27. Kudo Y, Iwashita M, Iguchi T, Takedu Y. The regulation of L-proline transport by insulin-like growth factor-1 in human osteoblasts-like SaOS-2 cells. Pflugers Arch 1996; 432: 419-25.
28. Laron Z, Klinger B. Effect of insuline-like growth factor treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance). Eur J Endocrinol 1998; 138: 176-80.
29. Ohneda K, Ulshen MH, Fuller CR, D'Ercole AJ, Lund PK. Enhanced growth of small bowel in transgenic mice expressing human insulin-like growth factor 1. Gastroenterology 1997; 112: 444-54.
30. Gutierrez-Ospina G, Calikoglu AS, Ye P, D'Ercole AJ. In vivo effects of insulin-like growth factor 1 on the development of sensory pathways: analysis of the primary somatic sensory cortex (S1) of transgenic mice. Endocrinology 1996; 137: 5484-92.
31. Caufriez A, Reding P, Urbain D, Goldstein J, Copinschi G. Insulin-like growth factor: A good indicator of funtional hepatocellular capacity in alcoholic liver cirrhosis. J Endocrinol Invest 1991; 14: 317-21.
32. Cuneo RC, Hickman PE, Wallace JD, Teh BT, Ward G, Veldhuis JD, et al. Altered endogenous growth hormone secretory Kinetic and diurnal GH-inding protein profiles in adults with chronic liver disease. Clin Endocrinol (Oxf) 1995; 43: 265-75.
33. Donaghy A, Ross R, Wicks C, Hughes SC, Holly J, Gimson A, et al. Growth hormone theraphy in patients with cirrhosis: A pilot study of efficacy and safety. Gastroenterology 1997; 113: 1617-22.
34. Assy N, Hochberg Z, Amit T, Shen-Orr Z, Enat R, Baruch Y. Growth hormone-stimulated insulin-like growth factor (IGF-I) and IGF-binding protein-3 in liver cirrhosis. J Hepatol 1997; 27: 796-802.
35. Scharf JG, Schmitz F, Frystyk J, Skjaerbaek C, Moesus H, Blum WF, et al. Insulin-like growth factor-I serum concentrations and patterns of insulin-like growth factor binding proteins in patients with chronic liver disease. J Hepatol 1996; 25: 689-99.
36. Schmueli E, Stewart M, Alberti G, Record C. Growth hoemone, insulin-like growth factor-I and insulin resistence in cirrhosis. Hepatology 1994; 19: 322-8.
37. Chang TC, Lin JJ, Yu SC, Chang TJ. Absence of growth hormone receptor in hepatocellular carcinoma and cirrhotic liver. Hepatology 1990; 11: 123-6.
38. Donaghy AJ, Delhanty PJD, Ho KK, Williams R, Baxter RC. Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex sistem in human cirrhosis. J Hepatol 2002; 36: 751-8.
39. Shen XY, Holt RIG, Miell JP, Justice S, Portmann B, Postel-Vinay MC, et al. Cirrhotic liver expresses low levels of the full-length and truncated growth hormone receptors. J Clin Endocrinol Metab 1998; 83 (7): 2532-8.
40. Shmueli E, Miell JP, Stewart M, Alberti KGMM, Record CO. High insulin-like growth factor binding protein 1 levels in cirrhosis; Link with insulin resistence. Hepatology 1996; 24: 127-33.
41. Donaghy A, Ross R, Gimson A, Hughes SC, Holly J, Williams R. Growth hormone, insulin-like growth factor-I, and insulin-like growth factor binding proteins 1 and 3 in chronic liver disease. Hepatology 1995; 21: 680-8.
42. Petersen KF, Jacob R, West AB, Sherwin RS, Schulman GI. Effects of insulin-like growth factor I on glucose metabolism in rats with liver cirrhosis. Am J Physiol 1997; 273: E1189-93.
43. Gallego-Rojo FJ, González-Calvin JL, Muñoz-Torres M, Mundi JL, Fernández-Pérez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998; 28: 695-9.
44. Picardi A, Costa de Oliveira A, Muguerza B, Tosar A, Quiroga J. Low dosis of insulin-like growth factor 1 improve nitrogen retention and food efficiency in rats with early cirrhosis. J Hepatol 1997; 26: 191-202.
45. Castilla-Cortázar I, Prieto J, Urdaneta E, Pascual M, Nuñez M, Zudaire E, et al. Impaired intestinal sugar transport in cirrhotic rats: Correction by low dosis of insulin-like growth factor 1. Gastroenterology 1997; 113: 1180-7.
46. Castilla-Cortázar I, Picardi A, Tosar A, Ainzua J, Urdaneta E, García M, et al. Effect of insulin-like growth factor I on in vivo intestinal absorption of D-galactosa in cirrhotic rats. Am J Physiol 1999; 276: G637-G42.
47. Castilla-Cortázar I, Pascual M, Urdaneta E, Pardo J, Puche JE, Vivas B, et al. Jejunal microvilli atrophy and reduced nutrient transport in rats with advanced liver cirrhosis: improvement by Insulin-like growth factor I. BMC Gastroenterol 2004; 4: 12-20.
48. Pascual M, Castilla-Cortázar I, Urdaneta E, Quiroga J, García M, Picardi A, et al. Altered intestinal transport of amino acids in cirrhotic rats: the effect of insulin-like growth factor-I. Am J Physiol Gastrointest Liver Physiol 2000; 279: 319-24.
49. Pérez R, Castilla-Cortázar I, Núñez M, Pardo A, Mirpurdi E, García M, et al. IGF-I does not improve fat malabsorption in cirrhotic rats. J Physiol Biochem 2001; 57: 59-60.
50. Cemboriain A, Castilla-Cortázar I, García M, Quiroga J, Muguerza B, Picardi A, et al. Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. J Hepatol 1998; 28: 122-31.
51. Cemborain A, Castilla-Cortázar I, García M, Muguerza B, Delgado G, Díaz-Sánchez M, et al. Effects of IGF-I treatment on osteopenia in rats with advanced liver cirrhosis. J Physiol Biochem 2000; 56: 91-9.
52. Castilla-Cortázar I, Díez N, García-Fernández M, Puche JE, Díez-Caballero F, Quiroga J, et al. Hematotesticular barrier is altered from early stages of liver cirrhosis: effect of insulin-like growth factor 1. World J Gastroenterol 2004; 10: 2529-34.
53. Castilla-Cortázar I, García M, Quiroga J, Díez N, Díez Caballero F, Calvo A, et al. Insuline-like growth factor reverts testicular atrophy in rats with advanced cirrhosis. Hepatology 2000; 31: 592-600.
54. Castilla-Cortázar I, Aliaga-Montilla MA, Salvador J, García M, Delgado G, González-Barón S, et al. Insulin-like growth factor-I restores the reduced somatostatinergic tone controlling growth hormone secretion in cirrhotic rats. Liver 2001; 37: 215-9.
55. Lorenzo-Zúñiga V, Rodríguez-Ortigosa CM, Bartolí R, Martínez-Chantar ML, Martínez-Peralta L, Pardo A, et al. Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats. Gut 2006; 55: 1306-12.
56. Castilla-Cortázar I, García M, Muguerza B, Quiroga J, Pérez R, Santidrián S, et al. Hepatoprotective effects of insulin-like growth factor 1 in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology 197; 113: 1682-91.
57. Nissley P, Lopaczynski W. Insulin-like growth factor receptors. Growth Factors 1991; 5: 29-43.
58. Caro JF, Poulos J, Ittoop O, Pories WJ, Flickinger EG, Sinha MK. Insulin-like growth factor-I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest 1988; 81: 976-81.
59. García-Fernández M, Castilla-Cortázar I, Díaz-Sanchez M, Navarro I, Puche JE, Castilla A, et al. Antioxidant effects of insulin-like growth factor-I (IGF-I) in rats with advanced liver cirrhosis. BMC Gastroenterol 2005; 5:7.
60. Bedossa P, Houglum K, Trautwein C, Holstege A, Chojkier M. Stimulation of collagen alpha 1 (I) gene expression is associated with lipid peroxidation in hepatocellular injury: a link to tissue fibrosis? Hepatology 1994; 19: 1262-71.
61. Yamada S, Yamada M, Murawaki Y, Hirayama C. Increase in lipoperoxides and prolyl hydroxylase activity in rat liver following chronic ethanol feeding. Biochem Pharmacol 1990; 40: 1015-29.
62. Mc Cullough AJ. In: Rector WG, editor. Complications of chronic liver disease. St. Louis: Mosby Year Book Inc; MO; 1992. p. 182-211.
63. Muguerza B, Castilla-Cortázar I, García M, Quiroga J, Santidrián S, Prieto J. Antifibrogenic effect in vivo of low doses of insulin-like growth factor-I in cirrhotic rats. Biochim Biophys Acta 2001; 1536: 185-95.
64. Sanz S, Pucilowska JB, Liu S, Rodríguez-Ortigosa CM, Lund PK, Brenner DA, et al. Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury. Gut 2005; 54: 134-41.
65. Mirpuri E, García-Trevijano ER, Castilla-Cortázar I, Berasain C, Quiroga J, Rodríguez-Ortigosa C, et al. Altered liver gene expression in CCl4-cirrhotic rats is partially normalized by insulin-like growth factor-I. Int J Biochem Cell Biol 2002; 34: 242-52.
66. Skrtic S, Wallenius K, Gressner AM, Jansson JO. Insulin-like growth factor signaling pathways in rat hepatic stellate cells: importance for deoxyribonucleic acid synthesis and hepatocyte growth factor production. Endocrinology 1999; 140: 5729-35.
67. Canturk NZ, Canturk Z, Ozden M, Dalcik H, Yardimoglu M, Tulubas F. Protective effect of IGF-I on experimental liver cirrhosisinduced common bile duct ligation. Hepatogastroenterol 2003; 50: 2061-6.
68. Johansson AG, Lindh E, Blum WF, Kollerup G, Sorensen OH, Ljunghall S. Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. Clin Endocrinol Metab 1996; 81: 44-8.
69. Rubin CD, Reed B, Shkhaee K, Pak CY. Treating a patient with the Werner syndrome and osteoporosis using recombinant human insulin. like growth factor. Ann Intern Med 1994; 121: 665-8.
70. Cioffi WG, Gore DC, Rue LW 3rd, Carrougher G, Guler HP, McManus WF, Pruitt BA Jr. Insulin-like growth factor-I lowers protein oxidation in patients with thermal injury. Ann Surg 1994; 220: 310-6.
71. Carroll PV, Umpleby M, Ward GS, Imuere S, Alexander E, Dunger D, et al. rhIGF-I administration reduces insulin requirements, decrease growth hormone secretion, and improves the lipid profile in adults with IDDM. Diabetes 1997; 46: 1453-8.
72. Moses AC, Young SC, Morrow LA, O'Brien M, Clemmons DR. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996; 45: 91-100.
73. Lai EC, Felice KJ, Festoff BW, Gawell MJ, Gelinas DF, Kratz R, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997; 49: 1621-30.
74. Vlachopapadopoulou E, Zachwieja JJ, Gertner JM, Manzione D, Bier DM, Matthews DE, et al. Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy - a clinical research center study. J Clin Endocrinol Metab 1995; 80: 3715-23.
75. Ibrahim YH, Yee D. Insulin-like growth factor-I and cancer risk. Growth Horm IGF Res 2004; 14: 261-9.
76. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 536-66.
77. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. BR-J-Cancer 1997; 76 (9): 1115-8.
78. Jenkins PJ, Fairclough PD, Richards T, Lowe DG, Monson J, Grossman A, et al. Acromegaly, clonic polyps and carcinoma. Clin Endocrinol (Oxf) 1997; 47: 17-22.
79. Hankinson SE, Willet WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulanting concentrations of insulin-like growth factor I and risk of breast cancer. Lancet 1998; 351: 1393-6.
80. Vadgama JV, Wu Y, Datta G, Khan H, Chillar R. Plasma insulin-like growth and serum IGF-I binding protein 3 can be asociated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 1999; 57: 330-40.
81. Juul A. Determination of insulin-like growth factor-I in the monitoring of growth hormone treatment with respect to efficacy of treatment and side effects: Should potential risks of cardiovascular disease and cancer be considered? Horm Res 1999; 51 (Supl. 3): 141-8.
82. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995; 55: 249-52.
83. Trojan J, Johnson TR, Rudin SD, Tykocinski ML, Ilan J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor-I RNA. Science 1993; 259: 94-7.
84. Conchillo M, de Knegt RJ, Payeras M, Quiroga J, Sangro B, Herrero JI, et al J. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: Results of a pilot randomized controlled clinical trial. J Hepatol 2005; 43: 630-6.
85. Caregaro L, Alberino F, Amodio P, Merkel C, Angeli P, Plebani M, et al. Nutritional and prognostic significance of insulin-like growth factor 1 in patients with liver cirrhosis. Nutrition 1997; 13: 185-90.
86. Caufriez A, Reding P, Urbain D, Goldstein J, Copinschi G. Insulin-like growth factor: A good indicator of funtional hepatocellular capacity in alcoholic liver cirrhosis. J Endocrinol Invest 1991; 14: 317-21.
87. Assy N, Hochberg Z, Enat R, Baruch Y. Prognostic value of generation of growth hormone-stimulated insulin-like growth factor-I (IGF-I) and its binding protein-3 in patients with compensated and descompensated liver cirrhosis. Dig Dis Sci 1998; 43: 1317-21.
88. Mazzioti G, Sorvillo F, Morisco F, Carbone A, Rotondi M, Stornaiuolo G, et al. Serum insilin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Cancer 2002; 95: 2539-45.
89. Inaba T, Saito H, Inoue T, Han I, Furukawa S, Matsuda T, et al. Growth hormone/insulin-like growth factor I axis alterations contribute to disturbed protein metabolism in cirrhosis patients after hepatectomy. J Hepatol 1999; 31: 271-6.
90. Min J, Yu H, Yan H, He L, Liu H, Zhao C. The growth hormone and insulin-like growth factors axis in liver failure patients. Zhonghua Gan Zang Bing ZaZhi 2001; 9 (Supl.): 76-8.
91. Möller S, Becker U, Juul A, Skakkebaek NE, Christensen E. Prognostic value of insulinlike growth factor I and its binding protein in patients with alcohol-induced liver disease. EMALD group. Hepatology 1996; 23: 1073-8.
92. Mendenhall CL, Chernausek SD, Ray MB, Gartside PS, Roselle GA, Grossman CJ, et al. The interactions of insulin-like growth factor I (IGF-I) with protein-calorie malnutrition in patients with alcoholic liver disease: V.A. Cooperative study on alcoholic hepatitis VI. Alcohol Alcoholism 1989; 24 (4): 319-29.
93. Wu YL, Ye J, Zhang S, Zhong J, Xi RP. Clinical significance of serum IGF-I, IGF-II, IGFBP3 in liver cirrhosis. World J Gastroenterol 2004; 10: 2740-3.